Affiliation:
1. Huntsman Cancer Institute University of Utah Health Sciences Center Salt Lake City Utah USA
2. Department of Pathology University of Utah School of Medicine Salt Lake City Utah USA
Abstract
SummaryCancer patients treated with immune checkpoint inhibitors (ICIs) are susceptible to a broad and variable array of immune‐related adverse events (irAEs). With increasing clinical use of ICIs, defining the mechanism for irAE development is more critical than ever. However, it currently remains challenging to predict when these irAEs occur and which organ may be affected, and for many of the more severe irAEs, inaccessibility to the tissue site hampers mechanistic insight. This lack of understanding of irAE development in the clinical setting emphasizes the need for greater use of preclinical models that allow for improved prediction of biomarkers for ICI‐initiated irAEs or that validate treatment options that inhibit irAEs without hampering the anti‐tumor immune response. Here, we discuss the utility of preclinical models, ranging from exploring databases to in vivo animal models, focusing on where they are most useful and where they could be improved.
Funder
National Cancer Institute
Subject
Immunology,Immunology and Allergy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献